Page last updated: 2024-08-23

fludarabine phosphate and Leukemia, Myeloid

fludarabine phosphate has been researched along with Leukemia, Myeloid in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anasetti, C; Mager, DE; McCune, JS; O'Donnell, PV; Salinger, DH; Sandmaier, BM; Vicini, P	1
Catovsky, D; Dearden, C; Kochethu, G; MacConkey, C; Matutes, E; Milligan, DW	1
Plunkett, W; Sampath, D	1

Trials

1 trial(s) available for fludarabine phosphate and Leukemia, Myeloid

Article	Year
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. British journal of haematology, 2006, Volume: 133, Issue:2 Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Transplantation Conditioning; Vidarabine Phosphate	2006

Article

Year

High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia.

British journal of haematology, 2006, Volume: 133, Issue:2

Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Transplantation Conditioning; Vidarabine Phosphate

2006

Other Studies

2 other study(ies) available for fludarabine phosphate and Leukemia, Myeloid

Article	Year
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Child; Cohort Studies; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Myeloid; Lymphocyte Count; Lymphopoiesis; Middle Aged; Models, Biological; Myeloproliferative Disorders; Reproducibility of Results; Retrospective Studies; Transplantation Conditioning; Vidarabine Phosphate; Young Adult	2015
The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage. Cancer research, 2000, Nov-15, Volume: 60, Issue:22 Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Caspases; DNA; DNA Damage; Enzyme Activation; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; S Phase; Tumor Cells, Cultured; U937 Cells; Vidarabine; Vidarabine Phosphate	2000

Article

Year

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:1

Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Child; Cohort Studies; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Myeloid; Lymphocyte Count; Lymphopoiesis; Middle Aged; Models, Biological; Myeloproliferative Disorders; Reproducibility of Results; Retrospective Studies; Transplantation Conditioning; Vidarabine Phosphate; Young Adult

2015

The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.

Cancer research, 2000, Nov-15, Volume: 60, Issue:22

Topics: Antineoplastic Agents; Apoptosis; Arabinonucleotides; Caspases; DNA; DNA Damage; Enzyme Activation; Humans; Leukemia, Myeloid; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; S Phase; Tumor Cells, Cultured; U937 Cells; Vidarabine; Vidarabine Phosphate

2000